Antimicrobial Susceptibility Testing Market Size, Share & Trends Analysis Report By Product, By Technique, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Market Size & Trends

The global antimicrobial susceptibility testing market size was valued at USD 3.42 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2023 to 2030. The market growth is attributed to increasing cases of various infectious diseases, growing adoption of personalized medicine, rising favorable initiatives taken by government bodies to reduce the burden of infectious diseases, and high antimicrobial resistance. Increasing cases of targeted diseases such as pneumonia & bloodstream infections caused by E.coli, K. pneumonia, P. aeruginosa, and others are increasing the adoption of antimicrobial susceptibility tests (AST). Moreover, increasing R&D activities to develop novel & effective therapeutic options for infectious diseases is increasing the penetration of AST in drug development activities.

For instance, the Global Antibiotic Resistance and Usage Surveillance System (GLASS) provides an annual analysis of AMR rates, testing coverage, trends, and systemic data on antimicrobial diseases in over 27 countries. Moreover, in 2020, the U.S. modified its national action plan for combating antibiotic-resistant bacteria (CARB). The global demand for antimicrobial susceptibility testing is also predicted to increase with the rising demand for personalized medicines and growing research activities to develop novel & effective treatments for infectious diseases.

Ongoing research activities related to effective therapeutics are expected to create new market opportunities in the coming years. For instance, according to a study published by NCBI in December 2021, a direct rapid antibiotic susceptibility test can detect antimicrobial resistance within 6 hours of a Gram smear result which can help to select appropriate antibiotics for the treatment of bacteremia in COVID-19 patients.

Increasing market penetration of personalized medicines and the overuse and misuse of antibiotics, which can lead to antimicrobial resistance (AMR) is anticipated to increase the adoption of AST for the treatment of infectious diseases. Furthermore, the increased use of antimicrobial susceptibility testing by biotechnological, pharmaceutical, and biopharmaceutical companies to develop novel & effective therapeutic options is further expected to drive market growth. The availability of advanced products also opens new opportunities for the market. For instance, in January 2023, NanoSynex Ltd. announced the company's plan to commercialize its innovative rapid AST.

Government bodies across the globe are forming strategies & policies to combat antimicrobial resistance. For instance, more than 2.8 million antimicrobial-resistant infections are reported each year in the U.S. Similarly, the incidence of drug-resistant diseases is higher in developing counties. Hence, increasing AMR cases are fueling the demand for antimicrobial susceptibility testing during the treatment of these diseases.

Product Insights

Based on the product, the manual tests segment held the largest market share of 53.27% in 2022. The high market share of the segment can be attributed to ease of availability and lower cost as compared to automated testing. Moreover, the growing prevalence rate of infectious diseases such as Shigella, Neisseria gonorrhoeae, Neisseria meningitides, and others are increasing the adoption of AST, which is expected to drive the segment growth over the forecast period.

However, automated testing is projected to grow at the fastest CAGR over the forecast period due to high accuracy and a lesser number of errors. Moreover, improving healthcare infrastructure, rising healthcare expenditure and technological advancements in testing instruments are further increasing market growth. Key players in the market are focusing on various strategic initiatives such as developing and launching new products to increase their dominance in the market. For instance, in April 2022, COPAN Diagnostics demonstrated its full range of automated solutions for identification & antimicrobial susceptibility testing (AST) at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022).

Technique Insights

Based on technique, the disk diffusion segment dominated the market in 2022 with a revenue share of 41.4%. The market growth can be attributed to various advantages such as ease of usage and cost-effectiveness. Moreover, it offers the possibility of executing direct susceptibility testing (DST), which shortens the turnaround time. However, the American Society for Microbiology (ASM), the British Society for Antimicrobial Chemotherapy (BSAC), and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have criticized DST as the inoculum used in such tests is not standardized.

The automated AST segment is projected to showcase the fastest growth rate over the forecast period as it offers the opportunity to predict drug resistance along with susceptibility testing. AST is a time-consuming process, but automation increases the speed of testing and repeatability. Moreover, the growing demand for personalized medicines further boosts the segment’s growth.

Application Insights

The susceptibility testing segment held the largest revenue share of 38.5% in 2022. The market share is attributed to the high prevalence of infectious diseases, increasing drug resistance, and rising adoption of AST to identify regimens for individual patients. Moreover, growing government initiatives to raise awareness about antimicrobial testing further fuel market growth. The growing prevalence of healthcare-associated infection (HAI) also increases the adoption of ASTs for the detection of microbes and effective treatment selection.

As per the report of CDC, there was a significant increase in the prevalence rate of HAIs such as VAE (12%), CAUTI (5%), MRSA (14%), CLABSI (7%), and SSI-HYST (11%), and between the year 2020 and 2021.

However, drug development is projected to showcase the fastest CAGR over the forecast period 2023-2030. The market growth is attributed to a growing focus on drug discovery due to the rising prevalence of drug-resistant infectious diseases, the growing geriatric population, and increasing R&D activities to develop novel therapeutics for these diseases. Increasing initiatives by the government to expand the pharmaceutical sector further boost the market growth over the forecast period. Moreover, increasing adoption of AST by pharmaceutical companies in clinical & preclinical drug development process is anticipated to increase the segment growth.

End-use Insights

Based on end-use, hospitals dominated the market, registering a 38.6% share of the market in 2022. The market growth is attributed to increasing hospital-acquired infections and rising cases of multi-drug resistant infectious diseases due to misuse and overuse of antibiotics and lack of awareness about the usage of antibiotics, mainly in developing regions. Susceptibility tests for different antimicrobials are also performed to identify suspected infections. In such cases, AST tests are highly effective in detecting the resistivity and sensitivity of microbes and help to choose the effective regimen.

However, the biotechnology & pharmaceutical companies segment is projected to grow at the fastest rate over the forecast period due to the rising focus on developing novel & effective treatments for infectious diseases. Furthermore, the increasing adoption of automated goods such as AST panels and cards and automated systems offers faster processing, higher accuracy, and improved work process, which further boosts the segment growth.

Growing adoption of personal medicines is fueling the market growth as AST are performed by healthcare professionals to detect antimicrobial regimes which are majorly effective for specific individuals. Technological advancements in AST, which promote higher efficacy and accuracy, further boost the segment's growth.

Regional Insights

North America dominated the overall market in 2022 with a revenue share of 46.3% and is anticipated to maintain its dominance throughout the forecast period. The rising cases of infectious diseases, growing antimicrobial-resistant conditions, and the increasing number of research activities related to introducing novel treatments for infections in the region are expected to drive regional market growth.

For instance, according to the Centers for Disease Control and Prevention (CDC), about 35,000 people die due to multi-drug-resistant diseases every year in the U.S. The increasing number of multidrug-resistant diseases boosts the need for antimicrobial susceptibility testing in the region.

However, the Asia Pacific region is projected to grow at the fastest CAGR over the forecast period. The rising number of activities related to research & development of novel therapeutics for infections, improving the healthcare sector, and government initiatives to reduce the disease burden are key factors driving the regional market growth. Moreover, increasing the adoption of tailored therapeutic options for treating infectious diseases is anticipated to boost the demand for antimicrobial susceptibility testing in the region.

Key Companies & Market Share Insights

The antimicrobial susceptibility testing industry is moderately fragmented, with the presence of a few major players and local players holding the majority of the share. Major players are focusing on various strategies to improve market growth and gain a larger market share. For instance, in August 2022, bioMérieux received the U.S. FDA approval for its SPECIFIC REVEAL Rapid Antimicrobial Susceptibility Test System, which is expected to increase the adoption of rapid AST during the treatment of antimicrobial resistance diseases. Some prominent players in the global antimicrobial susceptibility testing market include:

• Bio-Rad Laboratories Inc.

• Merck & Co., Inc.

• Thermo Fisher Scientific Inc.

• Danaher Corporation

• BD

• bioMérieux SA

• Creative Diagnostics

• Hi-Media Laboratories Pvt. Ltd.

• ELITechGroup

• F. Hoffmann-La Roche Ltd

Antimicrobial Susceptibility Testing Market Report Scope

Global Antimicrobial Susceptibility Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the subsegments from 2018 to 2030. For the purpose of this study, Grand View Research, Inc. has segmented the global antimicrobial susceptibility testing market report based on product, technique, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Manual Tests

    • MIC Strips

    • Susceptibility Testing Disks

    • Susceptibility Plates

  • Automated Instruments

  • Consumables & Media

• Technique Outlook (Revenue, USD Million, 2018 - 2030)

  • Automated AST

  • Etest Method

  • Dilution

  • Disk Diffusion

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Drug Development

  • Susceptibility Testing

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Diagnostic Laboratories

  • Biotechnology & Pharmaceutical Companies

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Spain

    • Italy

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait